Litcius/Paper detail

Single-domain antibodies directed against hemagglutinin and neuraminidase protect against influenza B viruses

Arne Matthys, Jan Félix, João Paulo Portela Catani, Kenny Roose, Wim Nerinckx, Benthe Van Buyten, Daria Fijałkowska, Nico Callewaert, Savvas N. Savvides, Xavier Saelens

2025Nature Communications6 citationsDOIOpen Access PDF

Abstract

Influenza B viruses are antigenically diverse and contribute significantly to the annual influenza burden. Here we report influenza B virus neutralizing single-domain antibodies that target highly conserved regions of the hemagglutinin and neuraminidase. Structural studies by single particle electron cryo-microscopy (cryo-EM) revealed that one of these single-domain antibodies prevents the conformational transition of the viral hemagglutinin to the post-fusion state by targeting a quaternary epitope spanning two protomers in the hemagglutinin-stem region. A second single-domain antibody broadly inhibits influenza B neuraminidase activity, including an oseltamivir-resistant neuraminidase, and its complex with neuraminidase elucidated by single particle cryo-EM established that it binds to residues in the neuraminidase catalytic site. Head-to-tail fusions of these single-domain antibodies led to bispecific binders that further improved the neutralization breadth and potency against influenza B viruses. These single-domain antibodies, fused to a human IgG1-Fc domain, fully protected female mice against an otherwise lethal influenza B virus challenge. Our findings underscore the potential of engineered single-domain antibodies to help control influenza B virus infections.

Topics & Concepts

NeuraminidaseVirologyHemagglutinin (influenza)AntibodyNeuraminidase inhibitorH5N1 genetic structureInfluenza A virusBiologyVirusCoronavirus disease 2019 (COVID-19)MedicineImmunologyInfectious disease (medical specialty)DiseasePathologyMonoclonal and Polyclonal Antibodies ResearchInfluenza Virus Research StudiesViral gastroenteritis research and epidemiology